Ranjana Advani, MD
Medical Oncology · Stanford
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- 17
- 3 carriers
- Office
- 1
Offices
1 location · Stanford Health Care · 3,152 clinicians in this group
Looking this up.
Hospitals listed: Stanford Health Care. That is not proof they admit you there this week.
Plans that list them
17 plans · 3 carriers
A missing listing does not mean out of network. Directories change, and a listing does not cover every office. Call Dr. Advani’s office at (650) 723-4000 to confirm they take your plan. Ask about the office you use, its medical group, referrals and appointments.
17 of 17 plans
| Alignment Health BreathEasy (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Clarity (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Harmony (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes CalPlus (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes Care (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Heart & Diabetes Choice (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Honor+ Plan (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health My Choice CalCare (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Silicon (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health smartHMO (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health the ONE (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| SCAN Balance (HMO C-SNP) | SCAN Health Plan | Listed | Oct 3, 2026 |
| SCAN Classic (HMO) | SCAN Health Plan | Listed | Oct 3, 2026 |
| SCAN MyChoice (HMO) | SCAN Health Plan | Listed | Oct 3, 2026 |
| SCAN Strive (HMO C-SNP) | SCAN Health Plan | Listed | Oct 3, 2026 |
| DualConnect (HMO D-SNP) | Santa Clara Family Health Plan | Listed | Sep 1, 2026 |
California Medical Board record
Licence A44422 · Current
Licensed to practise in California · since 1988 · expires 2027-09-30 · University of Bombay, Grant Medical College.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
Hospitals they work in
1 hospital
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- Stanford Health CareStanford, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency departmentPart of Stanford Health Care, which runs 3 hospitalsHome of Stanford Cancer Institute, a National Cancer Institute designated comprehensive cancer centrePatients rate it 4 of 5 · 83% would definitely recommend itOverall rating: 5 of 5 starsWorse than the national rate — Perioperative pulmonary embolism or deep vein thrombosis rate: 5.31 (4.24 to 6.37) · 8,661 cases, Jul 2022 – Jun 2024Worse than the national rate — Rate of inpatient admissions for patients receiving outpatient chemotherapy: 14.1 (12.7 to 15.7) · 2,191 cases, Jan 2024 – Dec 2024Better than the national rate — Postoperative respiratory failure rate: 4.08 (1.95 to 6.21) · 5,296 cases, Jul 2022 – Jun 2024Better than the national rate — Catheter Associated Urinary Tract Infections (ICU + select Wards): 0.317, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.446, Oct 2024 – Sep 2025Better than the national rate — SSI - Colon Surgery: 0.241, Oct 2024 – Sep 2025Better than the national rate — Ratio of unplanned hospital visits after hospital outpatient surgery: 0.7 (0.6 to 0.9) · 3,348 cases, Jan 2024 – Dec 2024
See every measure and the patient survey for Stanford Health Care
Behind the star rating — Deaths: 5 better, 3 the same, 0 worse of 8 measures. Safety: 3 better, 5 the same, 0 worse of 8 measures. Readmissions: 2 better, 5 the same, 4 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 5.31 (4.24 to 6.37) · 8,661 cases | Worse | Jul 2022 – Jun 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 14.1 (12.7 to 15.7) · 2,191 cases | Worse | Jan 2024 – Dec 2024 |
| Postoperative respiratory failure rateComplications and deaths | 4.08 (1.95 to 6.21) · 5,296 cases | Better | Jul 2022 – Jun 2024 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.317 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.446 | Better | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0.241 | Better | Oct 2024 – Sep 2025 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.7 (0.6 to 0.9) · 3,348 cases | Better | Jan 2024 – Dec 2024 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.06 (0.45 to 1.67) · 5,374 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.86 (0.72 to 1) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 166.09 (137.88 to 194.3) · 470 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 1.1 · 192 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 6.4 · 146 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 9.7 · 253 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 6.3 · 880 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 10.3 · 935 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 8.7 · 501 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 2.1 · 7,730 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.13 (0 to 0.27) · 20,799 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.28 (0.14 to 0.43) · 23,182 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 0.94 (0.2 to 1.68) · 5,694 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.36 (1.54 to 3.19) · 7,846 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 5.2 (3.76 to 6.64) · 5,603 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.38 (0.23 to 2.53) · 2,211 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.52 (0.21 to 0.83) · 19,915 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 3.6 · 416 cases | None | Apr 2023 – Mar 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.869 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.857 | No different | Oct 2024 – Sep 2025 |
| SSI - Abdominal HysterectomyInfections | 0.368 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 16.2 · 247 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 20.5 · 1,021 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 47.8 · 258 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -1.6 · 990 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 20.8 · 976 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 16.5 · 959 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 5.2 (4.4 to 6.2) · 2,191 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5.1 · 425 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 9.6 · 158 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 19.6 · 183 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 12.7 (10.4 to 15.4) · 4,578 cases | No different | Jan 2022 – Dec 2024 |
What patients said (6,810 patients answered, 25% of those asked)
| Cleanliness | 4 |
| Nurse communication | 4 |
| Doctor communication | 4 |
| Communication about medicines | 3 |
| Discharge information | 4 |
| Overall hospital rating | 4 |
| Quietness | 2 |
| Recommend hospital | 5 |
| Room was "always" clean | 75% |
| Nurses "always" communicated well | 82% |
| Doctors "always" communicated well | 81% |
| Staff "always" explained | 63% |
| Yes, staff "did" give patients this information | 89% |
| Yes, staff "did" give patients information about help after discharge | 89% |
| Doctors "always" explained things so they could understand | 76% |
| Doctors "always" listened carefully | 80% |
| Doctors "always" treated them with courtesy and respect | 87% |
| Patients who gave a rating of "9" or "10" (high) | 79% |
| Staff "always" explained new medications | 76% |
| Nurses "always" explained things so they could understand | 77% |
| Nurses "always" listened carefully | 79% |
| Nurses "always" treated them with courtesy and respect | 88% |
| "Always" quiet at night | 53% |
| "YES", patients would definitely recommend the hospital | 83% |
| Staff "always" explained possible side effects | 50% |
| Yes, staff "did" give patients information about possible symptoms | 90% |
Original Medicare doctor bills
$31,652
Medicare paid this office $31,652 for 158 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Long return visit (40+ min) | 51 | $13,225 | $122 |
| Return visit (30+ min) | 56 | $6,067 | $79 |
| Return visit (30+ min) | 28 | $3,673 | $118 |
| Short return visit (20+ min) | 31 | $3,141 | $79 |
| New patient visit (60+ min) | 16 | $2,433 | $152 |
See all 7 services
| Long return visit (40+ min) | 51 | $13,225 | $122 |
| Return visit (30+ min) | 56 | $6,067 | $79 |
| Return visit (30+ min) | 28 | $3,673 | $118 |
| Short return visit (20+ min) | 31 | $3,141 | $79 |
| New patient visit (60+ min) | 16 | $2,433 | $152 |
| Long return visit (40+ min) | 12 | $1,901 | $158 |
| Short return visit (20+ min) | 20 | $1,069 | $53 |
Who their Medicare patients are
158 Original Medicare patients in 2024. Average age 74 · Under 65 8% · 85 and older 8% · Women 42% · Also on Medicaid 10% · Health risk score 1.74. At or below the middle of the specialty; the typical medical oncology clinician is at 2.11.
Conditions among them: High blood pressure 54% · Coronary heart disease 25% · Diabetes 22% · Atrial fibrillation 20% · Cancer 18% · Depression 15% · Chronic kidney disease 13% · COPD 11% · Heart failure 10%.
The office billed $97,011, Medicare allowed $42,852 and paid $31,652; for 308 services of 7 kinds.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 158 | 308 | 74 | 1.74 | $97,011 | $31,652 |
| 2023 | 170 | 333 | 73 | 1.76 | $94,735 | $34,353 |
| 2022 | 162 | 357 | 74 | 1.62 | $81,832 | $32,079 |
| 2021 | 168 | 476 | 74 | 1.55 | $105,543 | $43,268 |
| 2020 | 165 | 459 | 74 | 1.83 | $88,514 | $35,939 |
| 2019 | 179 | 427 | 72 | 1.59 | $53,525 | $35,642 |
| 2018 | 164 | 398 | 72 | 1.48 | $44,977 | $30,779 |
| 2017 | 175 | 395 | 72 | 1.64 | $66,994 | $28,132 |
| 2016 | 195 | 387 | 72 | 1.65 | $87,835 | $30,675 |
| 2015 | 200 | 406 | 73 | 1.61 | $105,724 | $34,989 |
| 2014 | 226 | 478 | 73 | 1.64 | $122,429 | $40,568 |
| 2013 | 216 | 504 | 73 | 1.66 | $117,626 | $35,394 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 4 services
| Long return visit (40+ min) | 66 | $16,043 | $128 |
| Return visit (30+ min) | 89 | $9,925 | $82 |
| New patient visit (60+ min) | 26 | $4,259 | $164 |
| Short return visit (20+ min) | 37 | $2,417 | $51 |
2022: 4 services
| Return visit (30+ min) | 96 | $13,336 | $83 |
| Long return visit (40+ min) | 47 | $10,826 | $130 |
| Short return visit (20+ min) | 69 | $4,774 | $51 |
| New patient visit (60+ min) | 16 | $2,789 | $174 |
2021: 4 services
| Return visit (30+ min) | 100 | $17,635 | $87 |
| Long return visit (40+ min) | 53 | $12,440 | $123 |
| Short return visit (20+ min) | 87 | $7,095 | $52 |
| New patient visit (60+ min) | 29 | $5,458 | $188 |
2020: 4 services
| Long return visit (40+ min) | 70 | $14,662 | $95 |
| Return visit (30+ min) | 95 | $12,218 | $68 |
| New patient visit (60+ min) | 24 | $3,916 | $163 |
| Short return visit (20+ min) | 57 | $3,409 | $44 |
2019: 4 services
| Long return visit (40+ min) | 77 | $17,251 | $100 |
| Return visit (30+ min) | 121 | $12,877 | $64 |
| New patient visit (60+ min) | 30 | $4,569 | $152 |
| Short return visit (20+ min) | 17 | $604 | $34 |
2018: 4 services
| Return visit (30+ min) | 111 | $14,851 | $65 |
| Long return visit (40+ min) | 62 | $10,748 | $95 |
| New patient visit (60+ min) | 28 | $4,150 | $148 |
| Short return visit (20+ min) | 24 | $876 | $34 |
2017: 4 services
| Return visit (30+ min) | 109 | $14,116 | $64 |
| Long return visit (40+ min) | 42 | $7,298 | $99 |
| New patient visit (60+ min) | 29 | $3,888 | $134 |
| Short return visit (20+ min) | 60 | $2,718 | $39 |
2016: 4 services
| Long return visit (40+ min) | 72 | $12,749 | $96 |
| Return visit (30+ min) | 122 | $12,376 | $66 |
| New patient visit (60+ min) | 27 | $4,043 | $150 |
| Short return visit (20+ min) | 28 | $1,416 | $40 |
2015: 4 services
| Long return visit (40+ min) | 91 | $19,458 | $93 |
| Return visit (30+ min) | 101 | $7,615 | $59 |
| New patient visit (60+ min) | 49 | $7,201 | $147 |
| Short return visit (20+ min) | 12 | $501 | $39 |
2014: 4 services
| Long return visit (40+ min) | 99 | $18,439 | $95 |
| Return visit (30+ min) | 119 | $11,449 | $62 |
| New patient visit (60+ min) | 65 | $9,472 | $146 |
| Short return visit (20+ min) | 23 | $1,078 | $37 |
2013: 4 services
| Return visit (30+ min) | 155 | $15,828 | $59 |
| Long return visit (40+ min) | 83 | $12,067 | $89 |
| New patient visit (60+ min) | 38 | $5,260 | $138 |
| Short return visit (20+ min) | 35 | $1,919 | $41 |
Money from drug and device companies
$10,537 in 2025
| 2025 | 3 | 9 | $9,385 | $10,537 |
| 2024 | 3 | 8 | $12,933 | $20,110 |
| 2023 | 5 | 13 | $15,070 | $15,213 |
| 2022 | 5 | 9 | $16,909 | $17,051 |
| 2021 | 7 | 11 | $23,331 | $23,331 |
| 2020 | 8 | 8 | $13,344 | $13,344 |
| 2019 | 5 | 17 | $12,408 | $13,395 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| Pfizer | Adcetris | $5,424 | 4 payments
|
| Merck Sharp & Dohme | None | $3,355 | 2 payments
|
| F. Hoffmann-La Roche AG | None | $1,759 | 3 payments
|
See all 9 published payments
| F. Hoffmann-La Roche AG | Consulting · 2025-12-06 | None | $950 |
| F. Hoffmann-La Roche AG | Meals · 2025-12-06 | None | $49 |
| F. Hoffmann-La Roche AG | Consulting · 2025-07-08 | None | $760 |
| Pfizer | Consulting · 2025-07-02 | Adcetris | $2,160 |
| Pfizer | Consulting · 2025-06-24 | Adcetris | $2,160 |
| Pfizer | Meals · 2025-06-17 | Talzenna | $75 |
| Pfizer | Travel · 2025-06-17 | Talzenna | $1,028 |
| Merck Sharp & Dohme | Consulting · 2025-06-11 | None | $915 |
| Merck Sharp & Dohme | Consulting · 2025-01-08 | None | $2,440 |
See earlier years (2024, 2023, 2022, 2021, 2020, 2019)
2024: $20,110
| F. Hoffmann-La Roche AG | None | $15,311 | 5 payments
|
| Genmab U.S. | Epkinly | $2,663 | 2 payments
|
| Merck Sharp & Dohme | None | $2,135 | 1 payment
|
2023: $15,213
| F. Hoffmann-La Roche AG | None | $6,840 | 6 payments
|
| ADC Therapeutics America | None | $3,500 | 2 payments
|
| Merck Sharp & Dohme | None | $2,440 | 2 payments
|
| Genentech | Columvi | $2,420 | 2 payments
|
| BeiGene Switzerland GmbH | Brukinsa | $13 | 1 payment
|
2022: $17,051
| ADC Therapeutics America | None | $8,400 | 3 payments
|
| BeiGene Switzerland GmbH | Brukinsa | $4,267 | 2 payments
|
| F. Hoffmann-La Roche AG | None | $2,640 | 1 payment
|
| Takeda Pharmaceuticals U.S.A. | Adcetris | $1,084 | 1 payment
|
| Genentech | None | $660 | 2 payments
|
2021: $23,331
| Takeda Pharmaceuticals U.S.A. | Adcetris | $7,543 | 1 payment
|
| F. Hoffmann-La Roche AG | None | $3,960 | 2 payments
|
| Celgene | None | $3,250 | 2 payments
|
| Gilead Sciences | None | $2,850 | 1 payment
|
| Incyte | None | $2,768 | 2 payments
|
| Genentech | None | $2,310 | 1 payment
|
| Sanofi-Aventis U.S. | Sarclisa | $650 | 2 payments
|
2020: $13,344
| Daiichi Sankyo | None | $2,344 | 1 payment
|
| Epizyme | Tazverik | $2,050 | 1 payment
|
| Karyopharm Therapeutics | Xpovio | $1,938 | 1 payment
|
| BeiGene USA | Brukinsa | $1,625 | 1 payment
|
| Incyte | None | $1,538 | 1 payment
|
| Sanofi US Services | Sarclisa | $1,300 | 1 payment
|
| Sanofi-Aventis U.S. | Sarclisa | $1,300 | 1 payment
|
| Merck Sharp & Dohme | None | $1,250 | 1 payment
|
2019: $13,395
| Genentech | Venclexta | $4,781 | 5 payments
|
| Sanofi-Aventis U.S. | Isatuximab | $3,250 | 4 payments
|
| Seattle Genetics | Adcetris | $2,966 | 5 payments
|
| Celgene | Jcar017 | $2,305 | 2 payments
|
| F. Hoffmann-La Roche AG | Non-Covered Product | $93 | 1 payment
|
Research money
Money a company paid to run a study. Where it went to their institution, the clinician is named as an investigator and did not receive it; the amount covers the whole study, often across many sites.
| Merck Sharp & Dohme LLC · Phase 2 Study of Pembrolizumab and Chemotherapy in Patients With Newly Diagnosed Classical Hodgkin Lymphoma Keynote-C11 · 2022 | Their institution | $1,429,653 |
| Merck Sharp & Dohme LLC · A Phase 2 Study of Magrolimab and Pembrolizumab in Relapsed Or Refractory Classic Hodgkin Lymphoma · 2023 | Their institution | $755,602 |
| Merck Sharp & Dohme LLC · Phase 2 Study of Pembrolizumab and Chemotherapy in Patients With Newly Diagnosed Classical Hodgkin Lymphoma Keynote-C11 · 2023 | Their institution | $605,693 |
| Merck Sharp & Dohme LLC · Study Name#A Phase 2 Study of Magrolimab and Pembrolizumab in Relapsed Or Refractory Classic Hodgkin Lymphoma · 2024 | Their institution | $579,761 |
| Genentech, Inc. · Ph3 Study of Pola R Chp Glofit Vs Polar Chp in 1l Dlbcl · 2025 | Their institution | $415,381 |
| Janssen Research & Development, LLC · A Phase 3b, Multicenter, Open-Label, Pci-32765 (Ibrutinib) Long-Term Extension Study · 2019 | Their institution | $362,245 |
| Merck Sharp & Dohme LLC · A Phase 2 Study of Magrolimab and Pembrolizumab in Relapsed Or Refractory Classic Hodgkin Lymphoma · 2022 | Their institution | $328,483 |
| Regeneron Pharmaceuticals, Inc. · An Open-Label, Multi-Center Phase 1 Study To Investigate the Safety and Tolerability of Regn1979, An Anti-Cd20 X Anti-Cd3 Bispecific Monoclonal Antibody, in Patients With Cd20+ B-Cell Malignancies Previously Treated With Cd20-Directed Antibody Therapy · 2020 | Their institution | $197,996 |
| BeOne Medicines USA, Inc. · A Phase 1/2, Open-Label, Dose-Escalation and -Expansion Study of the Bruton Tyrosine Kinase Targeted Protein Degrader Bgb-16673 in Patients With B-Cell Malignancies · 2025 | Their institution | $194,663 |
| Takeda Pharmaceuticals U.S.A., Inc. · A Randomized, Open-Label, Phase 3 Trial of A+Avd Versus Abvd As Frontline Therapy in Patients With Advanced Classical Hodgkin Lymphoma · 2024 | Their institution | $194,145 |
| Seagen Inc. · A Dual-Cohort, Open-Label, Phase 2 Study of Brentuximab Vedotin and Chp (A+Chp) in the Frontline Treatment of Subjects With Peripheral T-Cell Lymphoma (Ptcl) With Less Than 10% Cd30 Expression · 2023 | Their institution | $184,254 |
| Janssen Research & Development, LLC · A Phase 3b, Multicenter, Open-Label, Pci-32765 (Ibrutinib) Long-Term Extension Study · 2020 | Their institution | $170,967 |
| Genentech, Inc. · Glofitamab Ctdna Study · 2024 | Their institution | $167,143 |
| Seattle Genetics, Inc. · A Pilot Study of Brentuximab Vedotin Combined With Avd Chemotherapy and 30 Gy Involved-Site Radiotherapy in Patients With Newly Diagnosed Early Stage, Unfavorable Risk Hodgkin Lymphoma · 2019 | Their institution | $153,240 |
| Merck Sharp & Dohme Corporation · Phase 2 Study of Pembrolizumab and Chemotherapy in Patients With Newly Diagnosed Classical Hodgkin Lymphoma Keynote-C11 · 2021 | Their institution | $147,924 |
| Seagen Inc. · A Phase 1/2 Study Evaluating Brentuximab Vedotin in Combination With Nivolumab in Patients With Relapsed Or Refractory Hodgkin Lymphoma After Failure of Frontline Therapy · 2020 | Their institution | $122,933 |
| Regeneron Pharmaceuticals, Inc. · An Open-Label, Multi-Center Phase 1 Study To Investigate the Safety and Tolerability of Regn1979, An Anti-Cd20 X Anti-Cd3 Bispecific Monoclonal Antibody, in Patients With Cd20+ B-Cell Malignancies Previously Treated With Cd20-Directed Antibody Therapy (Elm-1) · 2023 | Their institution | $115,423 |
| Seattle Genetics, Inc. · A Phase 12 Study Evaluating Brentuximab Vedotin in Combination With Nivolumab in Patients With Relapsed Or Refractory Hodgkin Lymphoma After Failure of Frontline Therapy · 2019 | Their institution | $86,282 |
| Merck Sharp & Dohme Corporation · A Phase 2 Study of Magrolimab and Pembrolizumab in Relapsed Or Refractory Classic Hodgkin Lymphoma · 2021 | Their institution | $82,150 |
| Merck Sharp & Dohme LLC · Phase 2 Study of Pembrolizumab and Chemotherapy in Patients With Newly Diagnosed Classical Hodgkin Lymphoma Keynote-C11 · 2024 | Their institution | $82,130 |
| Seagen Inc. · A Phase 1/2 Study Evaluating Brentuximab Vedotin in Combination With Nivolumab in Patients With Relapsed Or Refractory Hodgkin Lymphoma After Failure of Frontline Therapy · 2021 | Their institution | $81,204 |
| Genentech, Inc. · Ph3 Study of Pola R Chp Glofit Vs Polar Chp in 1l Dlbcl · 2024 | Their institution | $73,974 |
| PFIZER INC. · A Dualcohort Openlabel Phase 2 Study of Brentuximab Vedotin and Chp Achp in the Frontline Treatment of Subjects With Peripheral Tcell Lymphoma Ptcl With Less Than 10 Cd30 Expression · 2024 | Their institution | $73,715 |
| Janssen Research & Development, LLC · A Phase 3b Multi Center Open Label Pci32765 Ibrutinib Long Term Extension Study · 2021 | Their institution | $70,911 |
| ADC Therapeutics America, Inc. · A Phase 2, Open-Label, Single-Arm Study To Evaluate the Efficacy and Safety of Camidanlumab Tesirine (Adct-301) in Patients With Relapsed Or Refractory Hodgkin Lymphoma · 2022 | Their institution | $59,653 |
| Daiichi Sankyo Inc. · Ds3201-A-U202 · 2024 | Their institution | $45,334 |
| Gilead Sciences, Inc. · A Phase 2 Trial of Magrolimab (Anti-Cd47 Antibody) and Pembrolizumab in Patients With Relapsed Or Refractory Classic Hodgkin Lymphoma · 2023 | Their institution | $44,640 |
| Genentech, Inc. · Beti Dlbcl Phase Ib · 2019 | Their institution | $44,090 |
| BeiGene USA, Inc. · A Phase 1/2, Open-Label, Dose-Escalation and -Expansion Study of the Bruton Tyrosine Kinase Targeted Protein Degrader Bgb-16673 in Patients With B-Cell Malignancies · 2025 | Their institution | $43,404 |
| Merck Sharp & Dohme LLC · A Phase 2 Study of Magrolimab and Pembrolizumab in Relapsed Or Refractory Classic Hodgkin Lymphoma · 2025 | Their institution | $42,486 |
| Takeda Pharmaceuticals U.S.A., Inc. · A Randomized, Open-Label, Phase 3 Trial of A+Avd Versus Abvd As Frontline Therapy in Patients With Advanced Classical Hodgkin Lymphoma · 2020 | Their institution | $41,683 |
| Seagen Inc. · A Dual-Cohort, Open-Label, Phase 2 Study of Brentuximab Vedotin and Chp (A+Chp) in the Frontline Treatment of Subjects With Peripheral T-Cell Lymphoma (Ptcl) With Less Than 10% Cd30 Expression · 2022 | Their institution | $38,225 |
| Merck Sharp & Dohme Corporation · A Phase II Clinical Trial of Mk-3475 Pembrolizumab in Subjects With Relapsed Or Refractory R,R Classical Hodgkin Lymphoma Chl · 2021 | Their institution | $37,075 |
| BeiGene, Ltd. · A Phase 1/2, Open-Label, Dose-Escalation and -Expansion Study of the Bruton Tyrosine Kinase Targeted Protein Degrader Bgb-16673 in Patients With B Cell Malignancies · 2024 | Their institution | $30,327 |
| PFIZER INC. · Hd12 A Randomized Phase III Trial With A Pet Response Adapted Design Comparing Abvd Rt With A2vd Rt in Patients With Previously Untreated Stages Iaiia Hodgkin Lymphoma · 2025 | Their institution | $30,000 |
| Takeda Pharmaceuticals U.S.A., Inc. · A Randomized, Open-Label, Phase 3 Trial of A+Avd Versus Abvd As Frontline Therapy in Patients With Advanced Classical Hodgkin Lymphoma · 2021 | Their institution | $29,956 |
| Genmab A/S · Subcutaneous Epcoritamab With Or Without Lenalidomide As First Line Therapy for Diffuse Large B-Cell Lymphoma (Epcore Dlbcl-3) · 2025 | Their institution | $26,010 |
| Seagen Inc. · A Dual-Cohort, Open-Label, Phase 2 Study of Brentuximab Vedotin and Chp (A+Chp) in the Frontline Treatment of Subjects With Peripheral T-Cell Lymphoma (Ptcl) With Less Than 10% Cd30 Expression · 2021 | Their institution | $24,640 |
| Daiichi Sankyo Inc. · Ds3201-A-U202 · 2023 | Their institution | $21,575 |
| Daiichi Sankyo Inc. · Ds3201-A-U202 · 2022 | Their institution | $20,732 |
| Merck Sharp & Dohme LLC · A Multicenter, Open-Label, Phase 3 Study To Evaluate the Long-Term Safety and Efficacy in Participants Who Are Currently on Treatment Or in Follow-Up in Studies That Include Pembrolizumab · 2025 | Their institution | $19,060 |
| BeiGene, Ltd. · A Phase 1, Open-Label, Dose-Escalation and -Expansion Study of the Bruton Tyrosine Kinase-Targeted Protein-Degrader Bgb-16673 in Patients With B-Cell Malignancies · 2023 | Their institution | $17,222 |
| Regeneron Pharmaceuticals, Inc. · An Open-Label, Multi-Center Phase 1 Study To Investigate the Safety and Tolerability of Regn1979, An Anti-Cd20 X Anti-Cd3 Bispecific Monoclonal Antibody, in Patients With Cd20+ B-Cell Malignancies Previously Treated With Cd20-Directed Antibody Therapy (Elm-1) · 2024 | Their institution | $16,960 |
| Pharmacyclics LLC, An AbbVie Company · Pcyc-1127-CA · 2020 | Their institution | $16,681 |
| Merck Sharp & Dohme LLC · A Phase II Clinical Trial of Mk-3475 Pembrolizumab in Subjects With Relapsed Or Refractory R,R Classical Hodgkin Lymphoma Chl · 2023 | Their institution | $13,060 |
| Merck Sharp & Dohme LLC · A Phase II Clinical Trial of Mk-3475 Pembrolizumab in Subjects With Relapsed Or Refractory R,R Classical Hodgkin Lymphoma Chl · 2022 | Their institution | $12,653 |
| Takeda Pharmaceuticals U.S.A., Inc. · A Randomized, Open-Label, Phase 3 Trial of A+Avd Versus Abvd As Frontline Therapy in Patients With Advanced Classical Hodgkin Lymphoma · 2023 | Their institution | $10,628 |
| Janssen Research & Development, LLC · A Randomized Double-Blind Placebo Controlled Phase 3 Study of the Bruton'S Tyrosine Kinase Btk Inhibitor Pci32765 Ibrutinib in Combination With Bendamustine and Rituximab Br in Subjects With Newly Diagnosed Mantle Cell Lymphoma · 2023 | Their institution | $9,978 |
| Regeneron Pharmaceuticals, Inc. · An Open-Label, Multi-Center Phase 1 Study To Investigate the Safety and Tolerability of Regn1979, An Anti-Cd20 X Anti-Cd3 Bispecific Monoclonal Antibody, in Patients With Cd20 B-Cell Malignancies Previously Treated With Cd20-Directed Antibody Therapy · 2019 | Their institution | $9,353 |
| Pharmacyclics LLC, An AbbVie Company · Pcyc-1127-CA · 2019 | Their institution | $8,417 |
| Seattle Genetics, Inc. · A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study of Brentuximab Vedotin and Chp Achp Versus Chop in the Frontline Treatment of Patients With Cd30-Positive Mature T-Cell Lymphomas · 2019 | Their institution | $8,064 |
| Genentech, Inc. · Phase I Ib Study of Dcds0780a in Patients With Relapsed Or Refractory Nhl · 2019 | Their institution | $7,617 |
| Genentech, Inc. · Glofitamab Ctdna Study · 2025 | Their institution | $7,415 |
| Takeda Pharmaceuticals U.S.A., Inc. · A Randomized, Open-Label, Phase 3 Trial of A+Avd Versus Abvd As Frontline Therapy in Patients With Advanced Classical Hodgkin Lymphoma · 2025 | Their institution | $6,676 |
| Genentech, Inc. · Beti Dlbcl Phase Ib · 2020 | Their institution | $6,574 |
| Seagen Inc. · A Phase 1/2 Study Evaluating Brentuximab Vedotin in Combination With Nivolumab in Patients With Relapsed Or Refractory Hodgkin Lymphoma After Failure of Frontline Therapy · 2023 | Their institution | $6,464 |
| Janssen Research & Development, LLC · A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study of the Bruton'S Tyrosine Kinase (Btk) Inhibitor, Pci-32765 (Ibrutinib), in Combination With Bendamustine and Rituximab (Br) in Subjects With Newly Diagnosed Mantle Cell Lymphoma · 2020 | Their institution | $6,180 |
| Genentech, Inc. · Polarix · 2019 | This clinician | $5,280 |
| Seagen Inc. · A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study of Brentuximab Vedotin and Chp (A+Chp) Versus Chop in the Frontline Treatment of Patients With Cd30-Positive Mature T-Cell Lymphomas · 2020 | Their institution | $5,056 |
| Genentech, Inc. · Phase I Ib Study of Dcds0780a in Patients With Relapsed Or Refractory Nhl · 2020 | Their institution | $4,736 |
| Gilead Sciences, Inc. · A Phase 1b/2 Trial of Hu5f9-G4 in Combination With Rituximab Or Rituximab + Chemotherapy in Patients With Relapsed/Refractory B-Cell Non-Hodgkin'S Lymphoma · 2020 | Their institution | $4,392 |
| Regeneron Pharmaceuticals, Inc. · An Open-Label, Multi-Center Phase 1 Study To Investigate the Safety and Tolerability of Regn1979, An Anti-Cd20 X Anti-Cd3 Bispecific Monoclonal Antibody, in Patients With Cd20+ B-Cell Malignancies Previously Treated With Cd20-Directed Antibody Therapy · 2021 | Their institution | $4,352 |
| Celgene Corporation · A Phase 1b, Multi-Center, Open-Label Study of Novel Combinations of Cc-122, Cc-223, Cc-292, and Rituximab in Diffuse Large B-Cell Lymphoma and Follicular Lymphoma (Cc-122-Dlbcl-001) · 2019 | Their institution | $4,160 |
| Regeneron Pharmaceuticals, Inc. · An Open-Label, Multi-Center Phase 1 Study To Investigate the Safety and Tolerability of Regn1979, An Anti-Cd20 X Anti-Cd3 Bispecific Monoclonal Antibody, in Patients With Cd20+ B-Cell Malignancies Previously Treated With Cd20-Directed Antibody Therapy (Elm-1) · 2022 | Their institution | $3,840 |
| Regeneron Pharmaceuticals, Inc. · An Open-Label, Multi-Center Phase 1 Study To Investigate the Safety and Tolerability of Regn1979, An Anti-Cd20 X Anti-Cd3 Bispecific Monoclonal Antibody, in Patients With Cd20+ B-Cell Malignancies Previously Treated With Cd20-Directed Antibody Therapy (Elm-1) · 2022 | This clinician | $3,786 |
| Celgene Corporation · A Phase 1b, Multi-Center, Open-Label Study of Novel Combinations of Cc-122, Cc-223, Cc-292, and Rituximab in Diffuse Large B-Cell Lymphoma and Follicular Lymphoma · 2020 | Their institution | $3,456 |
| Merck Sharp & Dohme Corporation · A Phase II Clinical Trial of Mk-3475 Pembrolizumab in Subjects With Relapsed Or Refractory R,R Classical Hodgkin Lymphoma Chl · 2019 | Their institution | $3,434 |
| PFIZER INC. · Brentuximab Vedotin Clinical Publication Program · 2025 | This clinician | $3,200 |
| Regeneron Pharmaceuticals, Inc. · Regn1979-Clinical Development Program · 2020 | This clinician | $3,138 |
| Regeneron Pharmaceuticals, Inc. · An Open-Label, Multi-Center Phase 1 Study To Investigate the Safety and Tolerability of Regn1979, An Anti-Cd20 X Anti-Cd3 Bispecific Monoclonal Antibody, in Patients With Cd20+ B-Cell Malignancies Previously Treated With Cd20-Directed Antibody Therapy (Elm-1) · 2024 | This clinician | $2,726 |
| Janssen Research & Development, LLC · A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study of the Bruton'S Tyrosine Kinase (Btk) Inhibitor, Pci-32765 (Ibrutinib), in Combination With Bendamustine and Rituximab (Br) in Subjects With Newly Diagnosed Mantle Cell Lymphoma · 2019 | Their institution | $2,576 |
| Organon Llc · 2025 | Their institution | $2,560 |
| Seagen Inc. · A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study of Brentuximab Vedotin and Chp (A+Chp) Versus Chop in the Frontline Treatment of Patients With Cd30-Positive Mature T-Cell Lymphomas · 2021 | Their institution | $2,176 |
| Genentech, Inc. · Polarix · 2021 | This clinician | $2,145 |
| Genentech, Inc. · Ph1b 2 Tdb Chp Pola in Nhl for Dose Escalation Ph1b Followed By 1l Dlbcl for Expansion Ph2 · 2021 | This clinician | $1,980 |
| Merck Sharp & Dohme Corporation · A Phase II Clinical Trial of Mk-3475 Pembrolizumab in Subjects With Relapsed Or Refractory R,R Classical Hodgkin Lymphoma Chl · 2020 | Their institution | $1,745 |
| Regeneron Pharmaceuticals, Inc. · Regn1979-Clinical Development Program · 2019 | This clinician | $1,361 |
| F. Hoffmann-La Roche AG · Ph3 Study of Pola R Chp Glofit Vs Polar Chp in 1l Dlbcl · 2024 | This clinician | $878 |
| Daiichi Sankyo Inc. · Ds3201-A-U202 · 2021 | Their institution | $819 |
| Regeneron Pharmaceuticals, Inc. · An Open-Label, Multi-Center Phase 1 Study To Investigate the Safety and Tolerability of Regn1979, An Anti-Cd20 X Anti-Cd3 Bispecific Monoclonal Antibody, in Patients With Cd20+ B-Cell Malignancies Previously Treated With Cd20-Directed Antibody Therapy · 2021 | This clinician | $553 |
Checkups this office reported
Medicare did not publish checkup rates for this clinician.
- Medicare’s overall office score
- 76.5 / 100
- Scores the office’s reporting and systems. It is not a grade for how the doctor treats you.
Professional record
- NPI
- 1639225121
- Licence
- CA A44422California A44422: Current · expires 2027-09-30
- Group
- Stanford Health Care
- Video visits
- Lists video visits
- Gender
- Female
More record details
- Sole proprietor
- No
- Taxonomy
- Medical oncology (207RX0202X)
- Mailing address
- 300 Pasteur Dr, Stanford, CA, 94305
- NPI first listed
- 2007-01-26
- NPI last updated
- 2024-04-12
- NPI record certified
- 2024-04-12
This is when the NPI record was last certified, not a medical board exam.